Curr. Res. Health Sci., 2(2):28–40, 2024. DOI: 10.58613/crhs225

Current Research in Health Sciences

Journal homepage: https://www.gpub.org/journal-details.php?journal-id=47

ISSN (E): 2584-1084

Review Article

Brushing Away the Burden: How Art and Art Therapy Enhance Well-being for Breast Cancer Patients

Kavithaa Krishnamoorthy [1*], Senthilkumar Palanisamy [1], Aadersh Shibu [1] and Jesen Justus [2]

[1] *Department of Biotechnology, Hindusthan College of Arts & Science, Coimbatore, Tamilnadu, India*
[2] *Department of Animation and Visual Effects, Hindusthan College of Arts & Science, Coimbatore, Tamilnadu, India*
[*] *Corresponding author: k.kavithaa@hicass.ac.in*

Article Info

Keywords: *Cancer, Radiation therapy, Art therapy, Psychological facts, Survivors.*

Received: *18 October 2024*
Accepted: *19 November 2024*
Published: *3 December 2024*

© 2024 by the author's. The terms and conditions of the Creative Commons Attribution (CC BY) license apply to this open access article.

Abstract

One of the biggest threats to global health is cancer, a complex disease marked by uncontrolled cell development. This manuscript provides a comprehensive overview of cancer, elucidating its etiology, classification, and treatment modalities, with an emphasis on how art-based therapy can significantly improve the quality of life for cancer patients. Cancer encompasses a diverse spectrum of diseases, including breast cancer, lung cancer, colorectal cancer, and prostate cancer, each with distinct histological, molecular, and clinical characteristics. Treatment approaches vary based on cancer type, stage, and individual patient factors, encompassing surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Despite advancements in oncological care, cancer treatment often entails physical, emotional, and psychosocial challenges for patients. Art-based therapies, such as art therapy and creative expression interventions, emerge as invaluable adjunctive modalities in comprehensive cancer care. Through painting, drawing, sculpture, and other artistic mediums, cancer patients navigate the complexities of illness, finding solace, empowerment, and resilience amidst adversity. Art therapy fosters emotional processing, relaxation, and psychosocial support, enabling patients to cope with treatment-related stressors, enhance emotional well-being, and cultivate a sense of meaning and purpose on their cancer journey. Furthermore, art-based interventions contribute to patient empowerment, community building, and public awareness initiatives, amplifying the voices of cancer survivors and advocates. By integrating art into the fabric of cancer care, we can foster holistic healing and promote the welfare of patients affected by this formidable disease.

1. Introduction

Breast cancer, beyond its physical toll, often brings forth emotional distress and psychological upheaval [1]. Negative lifestyle choices and social psychological factors are linked to its occurrence. Studies show that genes and family history account for 5-10% of breast cancer cases, whereas potentially modifiable factors account for 20%-30% of cases [2]. Breast cells are where breast cancer starts. Malignant tumor is a collection of cancer cells that have the ability to spread and destroy nearby tissue. Moreover, it might spread throughout the whole body. Occasionally, changes occur in breast cells that prevent them from growing or operating normally. These changes could result in cysts, non-cancerous breast disorders, and typical hyperplasia. They might also result in non-cancerous cancers like intraductal papilloma [3]. Amidst the array of therapeutic interventions, art therapy has emerged as a promising avenue for holistic healing. Breast cancer, however, can sometimes result from changes to breast cells. Breast cancer typically originates in the cells lining the ducts, which are the tubes that carry milk from the glands to the nipple. This kind of breast cancer is known by the name "ductal carcinoma". Additionally, lobule

cells-collections of milk producing glands-can give rise to cancer [4, 5]. Lobular carcinoma refers to this specific type of malignancy. Both ductal and lobular carcinomas have the potential to be in situ, which indicates that the cancer is still contained in its original location and hasn't spread to adjacent tissues. Moreover, they might be invasive, which would indicate that they have entered the surrounding tissues [6]. There are many less prevalent ways that breast cancer might present itself. These consist of Paget disease, inflammatory breast cancer, and triple-negative breast cancer. Non-Hodgkin lymphoma and soft tissue sarcoma are two uncommon forms of breast cancer [7]. The primary risk factors for breast cancer are genetic factors, particularly family history, diet and obesity, as our nation's standard of living rises, women's weight increases and their dietary habits become more high-fat: smoking and alcohol consumption, ionizing radiation, and residual factors, particularly menstruation, childbirth, and lactation, this may also have an effect on breast cancer incidence. We should make an effort to limit the effects of exogenous hormones on our bodies by avoiding the everyday use of estrogen-containing cosmetics. There has been much discussion over these appeals [8]. Both genetic predispositions and environmental variables play a major role in initiating the multifactorial process of carcinogenesis. Cancer is one of the main causes of death worldwide, accounting for an unsettlingly high number of deaths. While many cancers may not always have to be fatal, they do generally result in markedly reduced quality of life and higher costs [9]. In India, the age-standardized incidence rate of female breast cancer increased by 39.1% between 1990 and 2016 in all 26 states. As the most frequent cancer in India, accounting for 28.2% of all cancers affecting women, 216,108 cases are predicted by 2022.

To manage the side effects of cancer and cancer treatment, highly successful pharmaceutical and alternative medicines have been created recently. One kind of complementary therapy meant to help people live better is art therapy [10]. Cathy Malchiodi, one of the pioneers in the field of art therapy for cancer patients, has stated that therapeutic approaches should be tailored to the individual psychological needs of each patient and that the chosen therapy should be arranged in line with those needs. Studies where the objectives of arts therapy were to improve patients' and their family's quality of life produced positive results [11, 12]. Art treatment encompass a variety of artistic disciplines, including writing, creative drama, collage, dancing, and painting [13]. It is easier to communicate feelings and experiences when one uses art as a form of language or as a tool [14]. Studies have shown that it can improve the mental well-being of those with psychological or physical problems by lowering tension, worry, and fear. It can also enhance the effectiveness of medical therapies for these individuals [15].

This review delves into the profound influence of art therapy on breast cancer patients, elucidating its mechanisms and its ability to induce relaxation and emotional well-being.

2. Epidemiology of Cancer

A broad category of illnesses cancer varies in incidence, prevalence, and fatality rates among various demographic groups and geographical areas. The World Health Organization (WHO) estimates that cancer causes 10 million deaths yearly, making it the second most common cause of death worldwide. Worldwide, breast cancer is the most common malignant tumor in women. Up to 36% of cancer patients are diagnosed with breast cancer. An estimated 2.26 million women were diagnosed with breast cancer in 2020 [16]. The 2018 GLOBOCAN statistics show a strong and positive correlation between the Human Development Indec (HDI) and age-standardized incidence rates (ASIR) of breast cancer [17]. As for the 2020 data, the ASIR showed the highest value in the every high HDI countries (75.6 per 100,000), while it was more than 200% lower in the middle and low HDI countries (27.8 per 100,000 and 36.1 per 100,000, respectively) [16]. The mortality-to-incidence ratio (MIR) for breast cancer in 2020 indicated that the global 5-year survival rate was 0.30 [18]. With respect to the clinical stage of illness, established healthcare facilities such as Hong Kong, Singapore, and turkey had 5-year survival rates for localized and regional breast cancer of 75.4% and 89.6% respectively. In less industrialized countries like Costa Rica, India, The Philippines, Saudi Arabia, and Thailand, the survival rates for localized and regional breast cancer were 47.4% and 76,3%, respectively [19]. Population growth, aging, and changing lifestyles are expected to contribute to an increase in the cancer burden, especially in low-and middle-income nations.

Risk Factors

A complicated interaction of genetic, environmental, and behavioral variables leads to cancer. While some cancers are influenced by genetic predisposition, the majority of cases are attributed to modifiable risk factors, including tobacco use, unhealthy diet, physical inactivity, alcohol consumption, and exposure to carcinogens such as ionizing radiation and environmental pollutants. Infectious agents such as human papillomavirus (HPV), hepatitis B virus (HBV), and Helicobacter pylori (H. pylori) also contribute to the development of certain cancers. Although the precise origin of carcinogenesis is still unknown, there are a number of risk factors that have been linked to the



Figure 1: Certain Risk Factors Causing Cancer [20]

development of breast cancer. The epidemiology data described above imply that a country's gender, age, and economic growth level are among the most important determinants. Hormonal factors are equally important; they include the number of children born, the age at which the first child is born, and nursing. Breast cancer development is mostly influenced by genetics, hormone replacement therapy, poor nutrition, and obesity [21].

Sex

At 99 percent, women are the ones who get breast cancer. In Poland, just 1% of instances of this malignant tumor impact men, according to the standardized occurrence rate of 0.4/105. The number of instances reported annually is limited to 100 [22]. However, there is a steady upward trend in both male and female breast cancer incidence, perhaps due to obesity and longer living durations [23].

Age

Among the most significant risk factors for breast cancer is age. The incidence of breast cancer has increased globally, with women under 50 experiencing the biggest increase in this age range. This malignant tumor, which is unusual in this age range, has taken a worse course and continues to pose a serious clinical and social problem. Results from serval research indicate that HER-2 receptor overexpression, marginal steroid receptor expression, increased histological malignancy, or the molecular biological subtype described as "basal-like" (sometimes called "triple negative") are the characteristics of breast cancer in young women [24].

Genetic Factor

Only 5-10% of incidences of breast cancer are genetically based. The BRCA1 and BRCA2 genes are the most well-known genetic abnormalities linked to this malignancy [25]. The suppressor gene BRCA1, located on chromosome 17, encodes nuclear protein, which is responsible for maintain genome integrity. This protein forms a complex with other suppressor gene products that binds to RNA polymerase II and interacts with histone deacetylase to influence transcription, DNA repair, and recombination processes. Homologous recombination heals double strand breaks, and it is specially made possible by the suppressor genes on chromosome 13 that encode the BRCA1 protein and the BRCA2 gene product [26]. Only 5-10% of incidences of breast cancer are genetically based. The BRCA1 and BRCA2 genes are the most well-known genetic abnormalities linked to this malignancy [25]. The suppressor gene BRCA1, located on chromosome 17, encodes nuclear protein, which is responsible for maintain genome integrity. This protein forms a complex with other suppressor gene products that binds to RNA polymerase II and interacts with histone deacetylase to influence transcription, DNA repair, and recombination processes. Homologous recombination heals double strand breaks, and it is specially made possible by the suppressor genes on chromosome 13 that encode the BRCA1 protein and the BRCA2 gene product [26].

Alcohol Consumption

Numerous studies indicate a link between alcohol consumption and an increased risk of breast cancer [27]. There are multiple reasons underlying this reliance. First of all, alcohol blocks the liver's ability to metabolize estrogens and accelerates the conversion of androgens to estrogens, which raises the blood levels of these molecules. Moreover, it could promote cell migration and proliferation while impeding the immune system or the DNA repair mechanism. Lastly, alcohol itself has metabolites that cause cancer [28]. The predicted risk of breast cancer is increased by 9% for each 10g of pure alcohol consumed daily.

Diet

Numerous studies have looked at how food composition affects how long a cancer takes to develop. It appears indisputable that a diet high in saturated fats, particularly those derived from animals, and poor in variety increases the risk of developing colon cancer in particular [29]. Nonetheless, the research assessing the relationship between diet and the risk of breast cancer is inconsistent. Dandamudi and colleagues examined comprehensive research works released from 2013 to 2017.Ten of the seventeen publications that were analyzed looked at the connection between "unhealthy" diet and the risk of breast cancer. The principal components of the diet under scrutiny were refined grains, salted food (chips, chips, peanuts), processed fruits juices, red and processed meats, solidified lipids, saturated fats, sweetened soft drinks, and sweetened goods (sweets, desserts). A substantial correlation was discovered in the majority of the examined studies, however not all of them, between the overindulgence in the aforementioned goods and a higher chance of breast cancer development. The primary variables impacting this connection were saturated fats, salt, and excessive consumption of red and processed meat [30].

Obesity

The link between obesity and breast cancer risk has been established by numerous studies. Jiralerspong and Goodwin gathered a pooled analysis of several studies evaluating the relationship between obesity and the risk of breast cancer in premenopausal and postmenopausal women. Findings from this study suggested that obesity and overweight related to not using hormone replacement therapy increased the risk of breast cancer, particularly steroid-receptor-expressed breast cancer, in postmenopausal women [31].

Obesity is known to raise the risk of breast cancer and relapses even in people who receive the appropriate care. Breast reconstruction is less common in obese women than in normal weight women, and surgical problems are more common in those whose who have had surgery. In obese women, the effectiveness of hormonal therapy and systemic chemotherapy is lower. Obese women are more likely to experience a local recurrence than women of normal weight. Treatment for breast cancer is often less successful in obese women who survive the disease [32].

3. Global Patterns and Disparities

Cancer exhibits substantial geographic variation in its distribution and incidence rates. High-income countries typically report higher incidence rates of cancer, attributed in part to improved cancer detection and healthcare infrastructure. However, disparities exist within and between countries, with marginalized populations facing greater barriers to cancer prevention, early detection, and access to quality care. Addressing these disparities is essential for achieving equitable cancer outcomes worldwide. Breast cancer incidence and death rates have increased within the last three decades. Between 1990 and 2016, the incidence of breast cancer increased by more than two-fold in 60 out of 102 nations, while 43 out of 102 countries have seen a twofold increase in disease-related deaths [33]. Current projections state that by 2030, there will be 2.7 million new cases detected annually worldwide, as opposed to 0.87 million fatalities [16]. Westernized lifestyles (later pregnancies, less breastfeeding, early menarche age, inactivity, and unhealthy diets) have led to increased cancer diagnosis rates, we expect low- and middle-income countries to have an even higher incidence of breast cancer [34].

4. Common Types of Cancer

The burden of cancer is dominated by a few common types, including lung, breast, colorectal, prostate, and stomach cancers. However, the distribution of cancer types varies by region, reflecting differences in risk factor exposure, genetic predisposition, and screening practices. For instance, heavy tobacco consumption areas are more likely to have lung cancer, whereas high-income nations with extensive mammography screening systems are more likely to have breast cancer.

Types of Breast Cancer

Ductal Carcinoma In Situ (DCIS)

The earliest type of breast cancer, known as DCIS, is defined by aberrant cells that are restricted to the milk ducts. DCIS is also known as Premalignant neoplasia Figure 2, where it is bordered by a layer of semicontinuous myoepithelial cells and it does not penetrate the basement membrane [35]. While non-invasive, DCIS can progress to invasive breast cancer if left untreated. Although cattegorized, DCIS is actually a diverse collection of lesions with differing clinical presentations, genetic makeup, biomarkers, morphologic characteristics, and clinical likelihood for developing into invasive breast cancer [36]. Diagnosis typically involves mammography, and treatment option



Figure 2: Ductal Carcinoma In Situ (DCIS) and Invasive Ductal Carcinoma [37]

include lumpectomy, mastectomy with sentinel lymph node biopsy, and radiation therapy, aiming to prevent disease recurrence and progression [38]. Nonetheless, a tissue sample is necessary for the diagnosis of DCIS. Although DCIS was rare before 1980, it currently makes up over 20% of all new diagnoses of breast cancer in US, with over 60000 new cases reported annually.

Invasive Ductal Carcinoma (IDC)

Approximately 80% of all cases of breast cancer are diagnosed as invasive ductal carcinoma (IDC) making it the most prevalent kind of disease. IDC, the most common form of breast cancer, originates in the milk ducts and infiltrates surrounding breast tissue. Individual (single) cells, diffuse sheets are the many growth forms of IDC Figure 2. Generally speaking, tubular distinction is either highly developed, hardly noticeable, or nonexistent [39]. While invasive ductal carcinoma (IDC) ca strike anyone at any age, postmenopausal women are the most likely to be diagnosed with the disease. A number of risk factors, including age, family history of breast cancer, genetic mutations (like those in BRCA1 and BRCA2), hormone replacement therapy, and specific lifestyle factors like alcohol and obesity, have been linked to the disease.

Histologically diverse, IDC encompasses subtypes such as tubular carcinoma, mucinous carcinoma, and medullary carcinoma, each with distinct prognostic implications. Treatment typically involves surgery, chemotherapy, radiation therapy, and targeted therapies based on tumor characteristics.

Invasive Lobular Carcinoma (ILC)

ILC arises from the lobules of the breast and accounts for approximately 10-15% of invasive breast cancers [40]. Figure 3 Lobular carcinomas originate from the epithelial cells seen in the breast terminal duct lobular unit [41]. Lack of the adhesion protein E-cadherin causes a variety of distinct features, such as a widespread development pattern in what are known as "single file lines," which is the hallmark trait of ILC [42].



Figure 3: Diagrammatic representation of Invasive Lobular Carcinoma [37]

Mutations in the E-cadherin gene, CDH1, cause ILC to lack functional E-cadherin. Although somatic mutations or methylation of CDH1 are present in most ILC tumors, germline mutations in CDH1 cause medical condition known as Hereditary Diffuse Gastric Cancer, it has a high lifetime chance of developing diffuse gastric cancer and ILC [43]. Characterized by Di-cohesive cells and a unique growth pattern, ILC poses diagnostic challenges and exhibits distinct clinical behavior compared to IDC. Treatment parallels that of IDC, albeit with considerations for the histological subtype.

Triple-Negative Breast Cancer (TNBC)

TNBC lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) Figure 4, making it refractory to hormone-targeted therapies and HER2-directed agents [44].



Figure 4: Receptors in Breast Cancer Cells and Triple Negative Breast Cancer [45]

The unusual metastatic patterns, aggressiveness, and absence of the targeted therapy are the defining characteristics of TNBC. An estimated 170,000 instances globally are thought to be TNBC, which makes up roughly 10-20% of invasive breast cancer occurrences [46]. Additionally, these patients have a history of early peak recurrence that occurred between the first and third year after diagnosis, in addition to more aggressive metastases that are more likely to develop in viscera, particularly the brain and lungs, rather than in the bone [47]. Histopathological analysis indicates that ductal origin accounts for most triple negative breast cancer cases; however, apocrine, adenoid cystic, and metaplastic aggressive phenotypes also seem overrepresented [48]. Aggressive in nature, Systemic chemotherapy is the main therapeutic strategy for TNBC due to its inferior results and restricted treatment options.

HER2-Positive Breast Cancer

HER2-positive breast cancer is characterized by overexpression of the HER2 protein, driving aggressive tumor growth. HER2- positive cancer cells have about two million HER2 proteins on their surface. Approximately 100 times as many as a normal cell [49]. Cells multiply and develop more quickly as a result of this overexpression of HER2. Dimerization of HER2 is a crucial phase in the signaling cascade

responsible for cancer progression [50]. HER2 represent a predominantly aggressive variant of the illness, with approximately one in five females worldwide receiving a diagnosis of breast cancer having HER2-positive breast cancer [51]. Breast cancer with HER2 positive status: the illness is still incurable. In contrast to other subtypes, HER2+ breast cancer therapy is quite challenging because there aren't many potential targets [52]. When paired with chemotherapy, therapies like trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM10 have transformed the way HER3-positive disease is managed, improving survival rates and lowering the risk of recurrence.

Hormone Receptor-Positive Breast Cancer

Hormone receptor-positive breast cancer, defined by expression of estrogen receptor (ER) and/or progesterone receptor (PR), comprises the majority of breast cancer cases. About 70% of cases of breast cancer are hormone receptor positive (HR+) cases [53]. Low TMB and low PD-L1 expression are characteristics of the more indolent HR+ subtype of breast cancer [54]. When estrogen stimulates the ER, distinct epigenetic events limit the recruitment of the ER to a fraction of its possible binding sites. This highly structured recruitment of the ER occurs at specific places across the genome. Endocrine therapies such as selective estrogen receptor modulators (e.g., tamoxifen), aromatase inhibitors, and ovarian suppression aim to block hormone signaling pathways, inhibiting tumor growth and reducing recurrence risk.

5. Emerging Trends and Challenges

Advancements in cancer research and treatment have led to significant improvements in survival rates and quality of life for cancer patients. Current projections state that by 2020, there will be 2.7 million new cases detected annually worldwide, as opposed to 0.87 million fatalities [16]. Due to westernized lifestyles, improved cancer detection, it is projected that in low- and middle- income countries, the prevalence of breast cancer would increase even further [55]. However, challenges persist, including the rising incidence of certain cancers such as melanoma and liver cancer, fueled by changing environmental and lifestyle factors. The treatment of breast cancer has significantly improved, but these developments have also brought forth a number of difficulties. Among the challenges brought about by these developments are.[56]
Cost and Availability Due to cost concerns or a lack of insurance, some patients may not be able to afford the many cutting-edge technologies and treatments available for breast cancer treatment [57]. Because of their limited financial resources, some patients may not be able to take advantages of the most recent medical developments, leading to inequities in access to care.
Health Inequalities There might be differences in access to these technologies even with the advancements in breast cancer care, especially for minority and unreserved groups. As always, addressing health disparities and ensuring equitable access to advancements in breast cancer treatment calls for attention and action [58].
Moral and Social Consequences There may be ethical and societal ramifications to personalized ramifications to personalized medicine and genomic testing in the treatment of breast cancer. Concerns regarding genetic privacy, discrimination based on genetic knowledge, and potential psychological repercussions of knowing one is genetically predisposed to breast cancer are a few examples of these. To safeguard patient's rights and welfare, these issues need to be carefully considered in terms of ethical and social ramifications.

Additionally, the increasing prevalence of cancer survivors underscores the need for survivorship care and long-term monitoring to address aftermath of cancer treatment and ensure optimal life.

6. Treatments Followed for Breast Cancer

Treatment for breast cancer has evolved throughout time. At the moment, treatment plans are customized for every patient according to her clinical condition, her unique traits, and her tumor. Treatment options range Figure 5 from a single modality to different combinations of radiation, chemotherapy, surgery, hormone therapy [59, 60]. Before suggesting a course of action, it is important to take into account various factors, including the patient's age and overall health, as well as the characteristics of the tumor, such as its type, histologic grade, burden, location, size, number of lesions, and degree of nodal involvement, as well as its biomarker and genetic status.



Figure 5: Common treatments of Breast Cancer [61]

Chemotherapy

Chemotherapy, a cornerstone of breast cancer treatment, is accompanied by a myriad of physical side effects ranging from nausea and hair loss to fatigue and neuropathy. It may be given in all circumstances, both pre- and post-surgery, depending on the condition of the patient. The duration of chemotherapy or radiation therapy is often dependent on the type of drug being used for breast cancer treatment. It is often specified over a period of three to six months, with days and weeks off in between to allow the body to recover from tumors [61]. Every medication used in chemotherapy, including vinorelbine (navelbine), Capacitabine (Xeloda), Doxorubicin (Doxil), Cyclephosphamide (Cytoxan), Carboplatinin (Paraplatin), and Docetaxel and Paclitaxel, has a different set of side effects, according to the American Cancer Society. Although treating the metastases and secondary breast may be more difficult, it is still manageable, even for several decades. Short-term side effects from chemotherapy can include hair loss, nausea, vomiting, mouth ulcers, stiffness in the finger or toenail, exhaustion, or decreased blood cell counts. Side effects like weight gain, memory and concertation issues brought on by a combination of medications, premature menopause, and exhaustion [61]. Beyond the physical, the uncertainty of treatment outcomes, fear of disease progression, and concerns about long-term toxicity contribute to heightened anxiety and distress among patients undergoing chemotherapy.

Radiation Therapy

Radiation therapy, also known as ionizing radiation, while crucial for local tumor control, often engenders its own set of stressors. This therapeutic approach in which tumor cells are exposed to radiation in order to break their DNA and induce cell death [62]. Patients with advanced cancer who are not responding to systemic therapy may be eligible for radiotherapy; this treatment option may be considered to help control tumor cells and distant metastases in these patients, as well as to improve patient safety. Radiation therapy has been shown to reduce cancer risk by approximately 50% or the risk of BC death by approximately 20% [61, 63]. Daily treatment sessions, logistical challenges, and concerns about radiation-induced side effects such as skin irritation and fatigue can exacerbate feelings of anxiety and apprehension. Moreover, the protracted nature of radiation therapy prolongs the psychological strain on patients, amplifying stress over time.

Surgical Interventions

Surgical interventions, including lumpectomy and mastectomy, evoke profound emotional responses due to their implications for body image, femininity, and self-esteem. Excision of a breast tumor or determination of disease's stage are the two primary goals of breast cancer surgery. Surgical treatment for BC involved the use of BCS and mastectomy. During BCS, only malignant tissues with a border of benign tissue is removed. A partial or total mastectomy is required to separate a whole breast. Unlike a radical mastectomy, which involves removing the underlying chest wall muscle, an improved radical mastectomy just involves removing the entire breast or underarm LNs [61]. The prospect of losing a breast, undergoing reconstructive surgery, and grappling with altered physical appearance can precipitate feelings of grief, loss, and profound psychological distress, exacerbating stress among breast cancer patients.

Hormonal Therapies

Hormonal therapies, such as tamoxifen and aromatase inhibitors, are often prescribed for hormone receptor-positive breast cancer. A variety of oral or injectable endocrine therapies appear to be available. These include aromatase inhibitors, selective ER down regulators, selective ER modulators, and analogues of gonadotrophin-releasing hormone [64]. Although HT drugs were longer to act, they nevertheless prevent positive tumors controlled by HRs from growing by keeping cancer cells from obtaining the hormones necessary for their proliferation [65]. Another related kind of HT is called ovarian suppression, which prevents the ovaries from being stimulated to produce estrogen through medication or surgery. Menopausal issues including hot flashes and joint and muscular joint discomfort are among the side effects brought on by HT [66]. While effective in reducing the risk of disease recurrence, these medications can induce menopausal symptoms, including hot flashes, vaginal dryness, and mood swings, significantly impacting patients' quality of life and contributing to psychological distress.

7. Importance of Art Therapy

Art therapy emerges as a potent adjunctive therapy in the comprehensive care of cancer patients, providing a creative outlet for emotional expression, coping, and healing. A type of emotional support called art therapy focuses on issues with psychological anguish with difficult emotions, as well as ideas about a problematic cancer diagnosis and treatment plan [67]. It is commonly anticipated that art therapy will improve cancer patients' quality of life when combined with other cancer treatments. The most current, thorough study examined how art therapy can help reduce emotional symptoms [68]. It has been demonstrated that art therapy generally aids people in exploring and developing their visual language and images [69, 70]. Through painting, drawing, sculpting, and other artistic mediums, patients navigate the complex terrain of illness, finding solace, empowerment, and resilience amidst adversity. Moreover, art therapy fosters relaxation, emotional processing, and psychosocial support, complementing conventional medical interventions and enhancing holistic well-being.

Patient Empowerment

Art empowers cancer patients to reclaim agency over their narrative, asserting their identity, dignity, and autonomy in the face of illness. Enhancing patient's psychological well-being and improving their quality of life are two of the intended uses of art therapy in cancer treatment processes [15]. Creative expression serves as a catalyst for self-discovery, self-expression, and personal transformation, enabling patients to transcend the limitations imposed by disease and redefine their relationship with their bodies, their illness, and their community. Through art, patients cultivate a sense of purpose, meaning, and hope, fostering inner strength and fortitude on their cancer journey. Cancer patients who receive art therapy are able to express themselves creatively and expressively via art, which is a form of language. They also mention better and more balance physical and mental health than those who do not receive art therapy [71].

Research and Innovation

Art-inspired research initiatives offer novel insights into the psychosocial, emotional, and existential dimensions of cancer, informing innovative approaches to patient care, survivorship, and end-of-life support. Any kind of expert intervention in medicine. For example, medical intervention refers to education, primary, secondary, tertiary, or quaternary care. They all follow the same procedures that is, expertise, mindset, and application [72]]. i.e., awareness of the availability of health care, the necessity of approaching them, the appropriate time to do so, people's attitudes toward that particular health care whether they seek medical attention, etc. The unsung heroes who are making it easier for the general public to receive health care are artists and the arts. Additionally, art has helped to lessen both physical and mental sickness [73]. By integrating artistic methodologies such as narrative medicine, visual storytelling, and participatory arts-based research, scholars uncover the lived experiences of individuals affected by cancer, elucidating the complex interplay of illness, identity, and meaning-making. Moreover, art-inspired interventions contribute to evidence-based practice, driving advancements in supportive oncology, palliative care, and survivorship programs.

Public Awareness and Advocacy

Art serves as a powerful catalyst for public awareness, education, and advocacy in the fight against cancer. Comics, illustrations, and cartoons grab the viewer's interest while effectively communicating a point to the general public. Public health communications. i.e., using funny, socially acceptable depictions of the process, significance, and ramifications of primordial and primary preventions through the use of visual diagrams, drawings, illustrations, etc., in order to promote greater female involvement in cancer awareness and screening [74]. Through exhibitions, performances, and community events, artists raise awareness about cancer prevention, early detection, and treatment options, fostering dialogue, empathy, and social change. Moreover, art amplifies the voices of cancer survivors, caregivers, and advocates, spotlighting their stories, struggles, and triumphs, and catalyzing collective action to address the systemic inequities and disparities inherent in the cancer care continuum [75].

Psychosocial Interventions

In addition to medical treatments, psychosocial interventions such as counseling, support groups, and mindfulness-based interventions play a pivotal role in addressing the emotional toll of breast cancer. The limbic system, cortex, and midbrain- three separate brain regions- are all positively impacted by art therapy techniques. Artworks such as installations, ceramics, and three-dimensional sculptures seem to aid in the development of motor skills. Maximizing the effectiveness of such works involves using materials with varying tissues and in a variety of colors, size, and forms [76]. However, navigating the complexities of accessing and engaging with psychosocial support services amidst the demands of treatment can pose additional stressors for patients, highlighting the need for comprehensive supportive care.

8. Influence Of Art Therapy In Breast Cancer Patients

Understanding Art Therapy

Art therapy harnesses the innate human capacity for self-expression through creative endeavors. By engaging in various artistic mediums such as painting, drawing, sculpting, and collage-making, individuals can externalize internal thoughts and emotions. This process facilitates introspection, emotional release, and personal growth, making it particularly conducive to addressing the multifaceted challenges of breast cancer [77].

The Therapeutic Journey

Breast cancer patients often grapple with anxiety, depression, body image issues, and existential concerns. People can safely address these difficult feelings in art therapy without being constrained by spoken words [78]. Through the act of creation, patients can explore their inner landscape, navigate existential questions, and find solace amidst turmoil.

Facilitating Relaxation

The creative process inherent in art therapy fosters relaxation by diverting attention away from distressing thoughts and promoting mindfulness. Engrossed in the present moment, patients experience a sense of flow, wherein worries dissipate, and inner peace prevails [79]. Moreover, the tactile nature of artistic mediums can evoke sensory pleasure, further enhancing relaxation.

Empowering Self-Expression

Breast cancer often disrupts one's sense of identity and autonomy. Art therapy empowers patients to reclaim agency over their narrative by externalizing their experiences in a tangible form. Through artistic expression, individuals can redefine their relationship with illness, assert their resilience, and cultivate a sense of empowerment amidst adversity.

Fostering Emotional Resilience

Art therapy cultivates emotional resilience by facilitating emotional processing and coping skill development. As patients engage in the creative process, they learn to confront difficult emotions, reframe negative narratives, and cultivate adaptive coping strategies [80]. Over time, this fosters emotional flexibility and psychological fortitude, enabling patients to navigate the challenges of illness with greater ease.

Building Supportive Communities

Art therapy often occurs in group settings, fostering camaraderie and social support amongst participants. Shared creative experiences facilitate bonding, empathy, and mutual understanding, mitigating feelings of isolation and fostering a sense of belonging [81]. Through collective expression, patients realize they are not alone in their struggles, instilling hope and solidarity.

9. How Art Therapy Distresses Cancer Patients

Art therapy offers a multifaceted approach to support cancer patients throughout their journey, influencing them in several beneficial ways.
Emotional Expression and Coping: Cancer patients can safely express complicated feelings about their diagnosis, course of treatment, and prognosis through art therapy [82]. The process of creating art allows the patient to develop ideas and communicate feelings. When patients engage in these activities, the power of color enhances their emotional state and supports their mode of expression. In addition to its significant impact at the conceptual and symbolic levels, colors routinely help patients learn new skills, hone existing ones, and work through process-related analytical challenges [83, 84]. Through creative expression, patients can externalize feelings of fear, anxiety, grief, and anger, facilitating emotional processing and coping.
Stress Reduction and Relaxation: Engaging in art-making activities promotes relaxation and reduces stress by diverting attention away from medical concerns and fostering mindfulness. Those who consistently engage in the creative arts process were shown to have a more composed attitude; conversely, the blood pressure was found to decrease due to the decreased stress, indicating that the involvement may have a secondary immune-boosting effect [85]. The tactile nature of artistic mediums, such as painting and sculpting, can induce a state of flow, wherein patients experience a sense of calm and well-being.
Empowerment and Agency: Art therapy empowers cancer patients to reclaim agency over their narrative, enabling them to assert their identity, dignity, and autonomy amidst illness. By creating artwork, patients cultivate a sense of mastery and control over their experiences, fostering resilience and self-efficacy.

Distraction and Distress Tolerance

Art therapy serves as a valuable distraction technique for patients undergoing stressful medical procedures or experiencing treatment-related side effects. Engaging in creative activities provides a reprieve from pain, discomfort, and existential concerns, enhancing distress tolerance and coping skills [86].

Social Connection and Support

Group-based art therapy sessions foster camaraderie, empathy, and mutual support among cancer patients, creating a sense of community and belonging. Shared creative experiences facilitate interpersonal connections, reduce feelings of isolation, and enhance social support networks.

Meaning-Making and Existential Exploration

Through art-making, cancer patients explore existential themes such as life, death, identity, and spirituality, fostering a sense of meaning and purpose in the face of illness. Art therapy facilitates existential reflection, helping patients reconcile existential concerns and find meaning amidst uncertainty.

Quality of Life and Well-being

Art therapy contributes to the holistic well-being of cancer patients by addressing their psychosocial, emotional, and spiritual needs. By promoting self-expression, emotional regulation, and social connectedness, art therapy enhances patients' overall quality of life and fosters resilience throughout the cancer journey [87, 88].

10. Conclusion

Cancer remains a formidable global health challenge, with far-reaching implications for individuals, communities, and societies. Understanding the epidemiology of cancer, including its risk factors, global patterns, and emerging trends, is essential for developing effective prevention strategies, early detection programs, and comprehensive cancer control efforts. By addressing the complex interplay of genetic, environmental, and social determinants of cancer, we can lessen its effects and work towards a time when cancer isn't the world's top cause of sickness and death.

Art transcends the confines of illness, imbuing the cancer experience with beauty, meaning, and resilience. From therapeutic interventions that nurture the soul to research endeavors that illuminate the human spirit, art enriches the field of cancer in myriad ways, offering solace, empowerment, and hope to all those touched by its brushstroke. As we continue to harness the transformative power of art in the fight against cancer, let us embrace creativity, compassion, and collaboration as cornerstones of healing, healing, and healing, and healing.

Art therapy offers a multifaceted approach to healing for breast cancer patients, encompassing emotional, psychological, and existential dimensions. By providing a creative outlet for self-expression, fostering relaxation, empowering individuals, and fostering supportive communities, art therapy emerges as a potent adjunctive therapy in the comprehensive care of breast cancer patients. As we continue to unravel its therapeutic potential, integrating art therapy into standard oncological care holds immense promise for enhancing the holistic well-being of patients traversing the challenging terrain of breast cancer.

In conclusion, art therapy emerges as a powerful tool in the holistic healing of breast cancer patients, addressing the multifaceted challenges of illness with creativity, compassion, and resilience. Through painting, drawing, sculpting, and other artistic mediums, patients find solace, empowerment, and emotional release amidst the turmoil of diagnosis, treatment, and survivorship. Patients can express

complicated emotions, work with existential issues, and regain control over their story in a therapeutic setting with art therapy, which helps them find meaning and purpose in the midst of hardship. Moreover, by fostering relaxation, reducing stress, and promoting social connection, art therapy enhances patients' overall well-being and quality of life throughout the cancer journey. As we continue to harness the transformative power of art in oncological care, let us embrace creativity as a cornerstone of healing, offering hope, comfort, and healing to all those affected by breast cancer.

References

[1] E. Ifeanyi Obeagu, Q. Babar, C. C. N. Vincent, C. Lawrence Udenze, R. Eze, C. J. Okafor, others, and F. Ngozi Amaeze. Therapeutic targets in breast cancer signaling: A review. 2021.

[2] Y. S. Sun, Z. Zhao, Z. N. Yang, F. Xu, H. J. Lu, Z. Y. Zhu, others, and H. P. Zhu. Risk factors and preventions of breast cancer. *International journal of biological sciences*, 13(11):1387, 2017.

[3] V. L. Ernster, R. Ballard-Barbash, W. E. Barlow, Y. Zheng, D. L. Weaver, G. Cutter, others, and B. M. Geller. Detection of ductal carcinoma in situ in women undergoing screening mammography. *Journal of the National Cancer Institute*, 94(20):1546–1554, 2002.

[4] A. Edward, E. I. Obeagu, H. M. Okorie, C. C. N. Vincent, and Y. S. Bot. Studies of serum calcium, inorganic phosphate and magnesium levels in lactating mothers in owerri. *Journal of Pharmaceutical Research International*, 33(41B):209–16, 2021.

[5] E. I. Obeagu, Y. A. Ahmed, G. U. Obeagu, U. O. Bunu, O. P. C. Ugwu, and E. U. Alum. Biomarkers of breast cancer: Overview. *Int. J. Curr. Res. Biol. Med.*, 1:8–16, 2023.

[6] G. Iatrakis and S. Zervoudis. Epidemiology of ductal carcinoma in situ. *Chirurgia (Romania)*, 116(5):S15–S21, 2021. Suppl.

[7] R. Jagsi, G. Mason, B. A. Overmoyer, W. A. Woodward, S. Badve, R. J. Schneider, others, and G. Susan. Komen-ibcrf ibc collaborative in partnership with the milburn foundation. *Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Research and Treatment*, 192(2):235–243, 2022.

[8] M. Mahdavi, M. Nassiri, M. M. Kooshyar, M. Vakili-Azghandi, A. Avan, R. Sandry, others, and V. Gopalan. Hereditary breast cancer; genetic penetrance and current status with brca. *Journal of cellular physiology*, 234(5):5741–5750, 2019.

[9] E. I. Obeagu and G. U. Obeagu. Breast cancer: A review of risk factors and diagnosis. *Medicine*, 103(3):e36905, 2024.

[10] G. Bar-Sela, L. Atid, S. Danos, N. Gabay, and R. Epelbaum. Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy. *Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer*, 16(11): 980–984, 2007.

[11] C. A. Malchiodi. *Medical art therapy with adults*. No Title, 1999.

[12] R. Thomas and H. Thomas. Effect of art therapy on breast cancer patients' quality of life: Literature review. *European Journal of Surgical Oncology*, 50, 2024.

[13] C. A. Malchiodi, editor. *Art therapy and health care*. Guilford Press, 2012.

[14] L. D. Hinz. *Expressive therapies continuum: A framework for using art in therapy*. Routledge, 2019.

[15] C. A. Malchiodi. *The art therapy sourcebook*. No Title, 2007.

[16] J. Ferlay, M. Laversanne, M. Ervik, F. Lam, M. Colombet, L. Mery, others, and F. Bray. *Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. Global Cancer Observatory: Cancer Tomorrow*. International Agency for Research on Cancer, Lyon, France, 2020.

[17] R. Sharma. Global, regional, national burden of breast cancer in 185 countries: evidence from globocan 2018. *Breast Cancer Research and Treatment*, 187:557–567, 2021.

[18] F. Asadzadeh Vostakolaei, H. E. Karim-Kos, M. L. Janssen-Heijnen, O. Visser, A. L. Verbeek, and L. A. Kiemeney. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. *The European Journal of Public Health*, 21(5):573–577, 2011.

[19] R. Sankaranarayanan, R. Swaminathan, H. Brenner, K. Chen, K. S. Chia, J. G. Chen, others, and N. Al-Hamdan. Cancer survival in africa, asia, and central america: a population-based study. *The lancet oncology*, 11(2):165–173, 2010.

[20] F. De Silva and J. Alcorn. A tale of two cancers: A current concise overview of breast and prostate cancer. *Cancers*, 14(12):2954, 2022.

[21] B. Smolarz, A. Z. Nowak, and H. Romanowicz. Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature). *Cancers*, 14(10):2569, 2022.

[22] U. Religioni. Cancer incidence and mortality in poland. *Clin. Epidemiol. Glob. Hearth*, 8:329–334, 2020.

[23] S. M. Lima, R. D. Kehm, and M. B. Terry. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. *EClinicalMedicine*, 38, 2021.

[24] E. Kudela, M. Samec, P. Kubatka, M. Nachajova, Z. Laucekova, A. Liskova, K. Dokus, K. Biringer, D. Simova, E. Gabonova, et al. Breast cancer in young women: Status quo and advanced disease management by a predictive, preventive, and personalized approach. *Cancers*, 11:1791, 2019.

[25] A. Mehrgou and M. Akouchekian. The importance of brca1 and brca2 genes mutations in breast cancer development. *Med. J. Islam. Repub. Iran*, 30:369, 2016.

[26] R. Roy, J. Chun, and S. N. Powell. Brca1 and brca2: Different roles in a common pathway of genome protection. *Nat. Rev. Cancer*, 12: 68–78, 2011.

[27] J. S. Khushalani, J. Qin, D. U. Ekwueme, and A. White. Awareness of breast cancer risk related to a positive family history and alcohol consumption among women aged 15–44 years in united states. *Preventive Medicine Reports*, 17:101029, 2020.

[28] K. Rojas and A. Stuckey. Breast cancer epidemiology and risk factors. *Clinical obstetrics and gynecology*, 59(4):651–672, 2016.

[29] G. Grosso, F. Bella, J. Godos, S. Sciacca, D. Del Rio, S. Ray, others, and E. L. Giovannucci. Possible role of diet in cancer: systematic review and multiple meta-analyses of dietary patterns, lifestyle factors, and cancer risk. *Nutrition reviews*, 75(6):405–419, 2017.

[30] A. Dandamudi, J. Tommie, L. Nommsen-Rivers, and S. Couch. Dietary patterns and breast cancer risk: a systematic review. *Anticancer Research*, 38(6):3209–3222, 2018.

[31] S. Jiralerspong and P. J. Goodwin. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. *Journal of Clinical Oncology*, 34(35):4203–4216, 2016. Jiralerspong, S., Goodwin, P. J. (2016). Obesity and breast cancer prognosis: evidence, challenges, and opportunities. Journal of Clinical Oncology, 34(35), 4203-4216.

[32] K. Lee, L. Kruper, C. M. Dieli-Conwright, and J. E. Mortimer. The impact of obesity on breast cancer diagnosis and treatment. *Current oncology reports*, 21:1–6, 2019.

[33] R. Sharma. Breast cancer incidence, mortality and mortality-to-incidence ratio (mir) are associated with human development, 1990–2016: evidence from global burden of disease study 2016. *Breast Cancer*, 26:428–445, 2019.

[34] P. Porter. Westernizing. *Women's Risks? Breast Cancer in Lower-Income Countries. New England Journal of Medicine*, 358(3):213, 2008.

[35] I. L. Wapnir, J. J. Dignam, B. Fisher, E. P. Mamounas, S. J. Anderson, T. B. Julian, others, and N. Wolmark. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in nsabp b-17 and b-24 randomized clinical trials for dcis. *Journal of the National Cancer Institute*, 103(6):478–488, 2011.

[36] S. Tomlinson-Hansen, M. Khan, and S. Cassaro. Breast ductal carcinoma in situ. 2021.

[37] T. H. Shah, E. Siores, and C. Daskalakis. Non-invasive devices for early detection of breast tissue oncological abnormalities using microwave radio thermometry. *Advances in Cancer Therapy*, 190:447–476, 2011.

[38] L. Romero, L. Klein, W. Ye, D. Holmes, R. Soni, H. Silberman, others, and M. J. Silverstein. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. *The American journal of surgery*, 188(4):371–376, 2004.

[39] F. Kanavati and M. Tsuneki. Breast invasive ductal carcinoma classification on whole slide images with weakly-supervised and transfer learning. *Cancers*, 13(21):5368, 2021.

[40] C. I. Li, B. O. Anderson, J. R. Daling, and R. E. Moe. Trends in incidence rates of invasive lobular and ductal breast carcinoma. *Jama*, 289(11):1421–1424, 2003.

[41] G. Dimri, H. Band, and V. Band. Mammary epithelial cell transformation: insights from cell culture and mouse models. *Breast Cancer Research*, 7:1–9, 2005.

[42] K. Johnson, D. Sarma, and E. S. Hwang. Lobular breast cancer series: imaging. *Breast Cancer Research*, 17:1–8, 2015.

[43] V. R. Blair, M. McLeod, F. Carneiro, D. G. Coit, J. L. D'Addario, J. M. van Dieren, others, and P. Guilford. Hereditary diffuse gastric cancer: updated clinical practice guidelines. *The Lancet Oncology*, 21(8):e386–e397, 2020.

[44] C. M. Perou. Molecular stratification of triple-negative breast cancers. *The oncologist*, 16(S1):61–70, 2011.

[45] M. Wahid. A., ul hussain, h., ghouri, h., khan, t., rehan. *S. T., Mumtaz, H*, PDL-1, PARP, and VEGFR inhibition: A potential combination regimen for targeting triple-negative breast cancer?. International Journal of Surgery:10–1097, 2023.

[46] S. A. O'Toole, J. M. Beith, E. K. Millar, R. West, A. McLean, A. Cazet, others, and S. R. Oakes. Therapeutic targets in triple negative breast cancer. *Journal of clinical pathology*, 66(6):530–542, 2013.

[47] C. Criscitiello, H. A. Azim Jr, P. C. Schouten, S. C. Linn, and C. Sotiriou. Understanding the biology of triple-negative breast cancer. *Annals of oncology*, 23:vi13–vi18, 2012.

[48] J. S. Reis-Filho, F. Milanezi, D. Steele, K. Savage, P. T. Simpson, J. M. Nesland, others, and F. C. Schmitt. Metaplastic breast carcinomas are basal-like tumours. *Histopathology*, 49(1):10–21, 2006.

[49] G. Sauter, J. Lee, J. M. Bartlett, D. J. Slamon, and M. F. Press. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. *Journal of Clinical Oncology*, 27(8):1323–1333, 2009.

[50] G. Lewis Phillips, D. Li G., D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, others, and M. X. Sliwkowski. Targeting her2-positive breast cancer with trastuzumab-dm1, an antibody–cytotoxic drug conjugate. *Cancer research*, 68(22):9280–9290, 2008.

[51] A. C. Wolff, M. E. H. Hammond, D. G. Hicks, M. Dowsett, L. M. McShane, K. H. Allison, others, and D. F. Hayes. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. *Journal of clinical oncology*, 31(31):3997–4013, 2013.

[52] H. M. Asif, S. Sultana, S. Ahmed, N. Akhtar, and M. Tariq. Her-2 positive breast cancer-a mini-review. *Asian Pacific Journal of Cancer Prevention*, 17(4):1609–1615, 2016.

[53] C. E. DeSantis, J. Ma, M. M. Gaudet, L. A. Newman, K. D. Miller, A. Goding Sauer, others, and R. L. Siegel. Breast cancer statistics. *2019. CA: a cancer journal for clinicians*, 69(6):438–451, 2019.

[54] A. Thomas, E. D. Routh, A. Pullikuth, G. Jin, J. Su, J. W. Chou, others, and L. D. Miller. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. *Oncoimmunology*, 7(10):e1490854, 2018.

[55] P. Porter. Westernizing. *Women's Risks? Breast Cancer in Lower-Income Countries. New England Journal of Medicine*, 358(3):213, 2008.

[56] R. Vidya, D. R. Leff, M. Green, A. S. McIntosh, E. S. John, C. C. Kirwan, L. Romics, and R. Cutress. Potter s., carmichael a., et al. innovations for the future of breast surgery. *Br. J. Surg.*, 108:908–916, 2021. doi: 10.1093/bjs/znab147.

[57] C. L. Soh, V. Shah, A. Arjomandi Rad, R. Vardanyan, A. Zubarevich, S. Torabi, others, and J. Malawana. Present and future of machine learning in breast surgery: systematic review. *British Journal of Surgery*, 109(11):1053–1062, 2022.

[58] V. Romeo, G. Accardo, T. Perillo, L. Basso, N. Garbino, E. Nicolai, others, and M. Salvatore. Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: A comparison of imaging modalities and future perspectives. *Cancers*, 13(14):3521, 2021.

[59] G. W. Sledge, E. P. Mamounas, G. N. Hortobagyi, H. J. Burstein, P. J. Goodwin, and A. C. Wolff. Past, present, and future challenges in breast cancer treatment. *Journal of clinical oncology*, 32(19):1979, 2014.

[60] S. Zhou, M. Yu, Z. Zhou, L. Wang, W. Liu, and Q. Dai. The effects of art therapy on quality of life and psychosomatic symptoms in adults with cancer: a systematic review and meta-analysis. *BMC Complementary Medicine and Therapies*, 23(1):434, 2023.

[61] A. Kumar. Comprehensive review on etiopathogenesis, treatment and emerging therapies of breast cancer. *Asian J Pharm Clin Res*, 14 (8):20–33, 2021.

[62] R. Baskar, K. A. Lee, R. Yeo, and K. W. Yeoh. Cancer and radiation therapy: current advances and future directions. *International journal of medical sciences*, 9(3):193, 2012.

[63] N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, others, and F. Cardoso. Breast cancer nat rev dis primers 5: 66. 2019.

[64] T. J. Yang and A. Y. Ho. Radiation therapy in the management of breast cancer. *Surgical Clinics*, 93(2):455–471, 2013.

[65] O. Pagani, M. M. Regan, B. A. Walley, G. F. Fleming, M. Colleoni, I. Láng, others, and P. A. Francis. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *New England Journal of Medicine*, 371(2):107–118, 2014.

[66] P. A. Francis, M. M. Regan, G. F. Fleming, I. Láng, E. Ciruelos, M. Bellet, others, and R. D. Gelber. Adjuvant ovarian suppression in premenopausal breast cancer. *New England Journal of Medicine*, 372(5):436–446, 2015.

[67] M. N. Azmawati, B. Boekhtiar, M. Zawiah, S. Aisah, W. L. Chiew, and R. Dalila. The efficacy of art therapy on mental health outcomes among breast cancer patients: the current state of evidence based on randomised controlled trials. *IIUM Medical Journal Malaysia*, 17 (2), 2018.

[68] J. Czamanski-Cohen, J. F. Wiley, N. Sela, O. Caspi, and K. Weihs. The role of emotional processing in art therapy (repat) for breast cancer patients. *Journal of Psychosocial Oncology*, 37(5):586–598, 2019.

[69] P. Luzzatto. From psychiatry to psycho-oncology: Personal reflections on the use of art therapy with cancer patients. In *Art therapy in palliative care*, pages 169–175. Routledge, 2015.

[70] P. Luzzatto and B. Gabriel. The creative journey: A model for short-term group art therapy with posttreatment cancer patients. *Art Therapy*, 17(4):265–269, 2000.

[71] T. Thompson, M. Learmonth, K. Huckvale, J. Beedell, M. Wood, S. Richardson, others, and S. Lewis. *Art therapy with physical conditions*. Jessica Kingsley Publishers, 2015.

[72] Y. Dalia, E. C. Milam, and E. A. Rieder. Art in medical education: a review. *Journal of graduate medical education*, 12(6):686–695, 2020.

[73] E. Powley and R. Higson. *The Arts in Medical Education: a practical guide*. CRC Press, 2017.

[74] D. G. Rabinowitz. On the arts and humanities in medical education. *Philosophy, Ethics, and Humanities in Medicine*, 16(1):4, 2021.

[75] T. Moniz, M. Golafshani, C. M. Gaspar, N. E. Adams, P. Haidet, J. Sukhera, others, and L. Lingard. How are the arts and humanities used in medical education? results of a scoping review. *Academic Medicine*, 96(8):1213–1222, 2021.

[76] S. D. Heath and S. Darley. The expressive arts activity book. 2008.

[77] S. M. Walsh, S. C. Martin, and L. A. Schmidt. Testing the efficacy of a creative-arts intervention with family caregivers of patients with cancer. *Journal of Nursing Scholarship*, 36(3):214–219, 2004.

[78] E. Bilgin, O. Kirca, and M. Ozdogan. Art therapies in cancer—a non-negligible beauty and benefit. *Journal of Oncological Sciences*, 4 (1):47–48, 2018.

[79] M. Murray. Levels of narrative analysis in health psychology. *Journal of health psychology*, 5(3):337–347, 2000.

[80] E. Predeger. Womanspirit: A journey into healing through art in breast cancer. *Advances in Nursing Science*, 18(3):48–58, 1996.

[81] C. Elbrecht. *Trauma healing at the clay field: A sensorimotor art therapy approach*. Jessica Kingsley Publishers, 2012.

[82] S. D. Heath and S. Darley. The expressive arts activity book. 2008.

[83] A. Visser and M. Op'T Hoog. Education of creative art therapy to cancer patients: Evaluation and effects. *Journal of Cancer Education*, 23(2):80–84, 2008.

[84] J. Kievisiene, R. Jautakyte, A. Rauckiene-Michaelsson, N. Fatkulina, and C. Agostinis-Sobrinho. The effect of art therapy and music therapy on breast cancer patients: what we know and what we need to find out—a systematic review. *Evidence-Based Complementary and Alternative Medicine*, 2020(1):7390321, 2020.

[85] H. L. Stuckey and J. Nobel. The connection between art, healing, and public health: A review of current literature. *American journal of public health*, 100(2):254–263, 2010.

[86] E. T. Weiner, L. Rappaport, and L. Rappaport. Mindfulness and focusing-oriented arts therapy with children and adolescents. In *Mindfulness and the arts therapies: Theory and practice*, pages 248–261. 2014.

[87] T. Thompson, M. Learmonth, K. Huckvale, J. Beedell, M. Wood, S. Richardson, others, and S. Lewis. *Art therapy with physical conditions*. Jessica Kingsley Publishers, 2015.

[88] A. M. Joshi, S. A. Mehta, N. Pande, A. O. Mehta, and K. S. Randhe. Effect of mindfulness-based art therapy (mbat) on psychological distress and spiritual wellbeing in breast cancer patients undergoing chemotherapy. *Indian journal of palliative care*, 27(4):552, 2021.